Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics
Advanced Science · 2026-03 · 13 (18)
DOI: 10.1002/advs.202521802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 12.02.2026. Verfasst von Yufei Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Autoimmune Diseases, Biomarkers, Bioengineering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Technology and Education of Zhejiang Province of China.
Abstract (Originalsprache)
Autoimmune diseases (ADs) are chronic disorders caused by a breakdown in immune self‐tolerance, triggering aberrant immune attacks against one's own tissues. These responses cause persistent inflammation and multiorgan damage. As the global prevalence of ADs continues to increase, they impose a growing public health burden, but current treatments do not meet clinical needs. Extracellular vesicles (EVs) are lipid bilayer membrane‐enclosed nanoparticles secreted by live cells that can carry diverse bioactive molecules and play essential roles in intercellular communication. Recently, EVs have attracted considerable attention as promising therapeutic candidates for ADs owing to their high biocompatibility, low immunogenicity, and ability to traverse biological barriers. This review systematically summarizes the current applications and development trends of both plant and mammalian sources and explores the functions of natural or engineered EVs in modulating the pathological processes underlying ADs. We also discuss the emerging potential of EVs as diagnostic biomarkers and targeted drug delivery systems for autoimmune conditions. Although clinical translation of EV‐based therapies faces challenges, deepening our understanding of the pathogenic roles of EVs in autoimmunity coupled with ongoing advances in bioengineering technologies holds promise for delivering novel theoretical insights and practical strategies for diagnosing and treating these refractory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
ORCID-Profile: Yufei Wu, Zai-Long Chi
Förderung
- National Natural Science Foundation of China
- Medical Technology and Education of Zhejiang Province of China
Zitieren
APA
Wu, Y., Ma, H., Zhu, T., Huang, S., Lu, M., Wang, Q., & Chi, Z. L. (2026). Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics. Advanced Science, 13(18). https://doi.org/10.1002/advs.202521802
Vancouver
Wu Y, Ma H, Zhu T, Huang S, Lu M, Wang Q, et al. Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics. Advanced Science. 2026;13(18). doi:10.1002/advs.202521802
BibTeX
@article{Wu2026,
author = {Wu, Yufei and Ma, Huiyuan and Zhu, Tinghui and Huang, Shuwei and Lu, Manxi and Wang, Qiong and Chi, Zai-Long},
title = {Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {18},
doi = {10.1002/advs.202521802}
}
EUVIMED